Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck remains one of the Pharma companies you should be paying the closest attention to at this point. It's one of the the largest and most diversified pharma companies on sale on the entire planet.

Merck - One Of The Best Pharma 'BUYS'

Merck continues to attract me for a long-term investment. The company has seen an eventful year, notably with the spinoff of Organon.

Merck - Murky Non-Keytruda Performance

Johnson & Johnson

My pair trade, long JNJ vs. short MRK suggestion has worked out well since December's article. Johnson & Johnson remains a smart accumulation idea, while I currently rate Merck a hold.

Revisiting My Long Johnson & Johnson Vs. Short Merck Call In 2020

The Keytruda-Lenvima combo was recently approved for its second oncology indication.

What This Label Expansion Means for Merck

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Leslie A. Brun Resigns from Merck Board of Directors

Leslie A. Brun Resigns from Merck Board of Directors

Amazon

Discovery

Discovery Communications

AT&T

Hillman Capital Management recently disclosed its 13F portfolio updates for the second quarter of 2021, which ended on June 30.

Hillman Capital's Top 2nd-Quarter Buys

Werewolf Therapeutics (HOWL) inks a collaboration and supply agreement with Merck to evaluate its candidate, WTX-124, in combination with Keytruda, for treating solid tumors. Stock up.

Werewolf (HOWL) Up on Deal With Merck for Solid Tumor Study

Adagene

Adagene Inc (NASDAQ: ADAG) has entered into a third clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). The agreement includes an open-label, dose-escalation, and expansion clinical study of ADG106 combined with Merck's Keytruda (pembrolizumab) in advanced or metastatic solid and/or hematological malignancies.

Adagene Inks Third Cancer Trial Collaboration With Merck

Kroger

Organon & Co

These were Berkshire Hathaway's biggest buys during Q2, 2021.

Top Stocks Warren Buffett Just Bought

Lockheed Martin

Sleep-well-at-night companies that pay growing income and have durable business models are a good fit for any portfolio. In this article, I highlight two wide-moat companies that fit this profile.

Build Your Dividend Factory: 2 'No Brainer' SWANs To Buy Now

Werewolf Therapeutics

Werewolf Therapeutics Inc (NASDAQ: HOWL) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK) to evaluate WTX-124 in combination with Keytruda (pembrolizumab). WTX-124 is a systemically delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE product candidate.

Werewolf Therapeutics Inks Solid Tumor Trial Collaboration With Merck

Franklin Resources

Chevron

Edison

Enterprise Products Partners

Flowers Foods

Gaming and Leisure Properties

Huntington Bancshares

Kinder Morgan

M.D.C. Holdings

Altria

Medical Properties Trust

Newmont Mining

Sturm, Ruger & Company

Retail Opportunity Investments

Unum

Vale S.A.

Valero Energy

Williams

Exxon Mobil

May-August, 2021, Kiplinger-Today listed eight-sets of stocks sorted as: best-buys for 2021, infrastructure-plays, value, growth, small-cap, high-yield, housing-bets, and cash-flow-gushers. Those eight "exceptional-dividend" articles revealed 86 equities. 76 pay-dividends. Kiplinger article-titles were, '21 Best Stocks to Buy'; '14 Best Infrastructure Stocks'; '16 Best Value; '10 Dividends-Growth'; '6 Small-Cap'; '10 High-Yield 4% or More;' '12 Housing; '10 Cash-Flow-Gushers.'

Kiplinger Exceptional August 2021 Dividends Features 13 Ideal Dogs

AbbVie

Biogen

Bristol-Myers

General Motors

Buffett stocks are a hot topic among investors as they look to go long on some fresh plays. Kroger and Aon are among Berkshire's favorites.

7 Buffett Stocks to Buy (and Sell) if You Want to Be Like Berkshire

Yesterday, Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway ( BRK.A , Financial)( BRK.B , Financial) published its 13F report for the period ending June 30.

Warren Buffett Sells Biotech Holdings After a Year

Buffett's company established stakes in Merck, AbbVie, and Bristol Myers Squibb in the second half of last year, yet it slashed all three positions.

Warren Buffett's Berkshire Hathaway sold Biogen, halved its Merck stake, and boosted its Kroger bet. Here's a closer look at its key trades in Q2.

Warren Buffett-led Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) sharply lowered its exposure in General Motors Co (NYSE: GM), Merck & Co Inc (NYSE: MRK), AbbVie Inc (NYSE: ABBV), Bristol-Myers Squibb Co (NYSE: BMY) and added positions in Kroger Inc (NYSE: KR) and Aon Plc (NYSE: AON), in the second quarter, regulatory filings revealed on Monday. What Happened: The Omaha, Nebraska-based conglomerate disclosed it has trimmed its position in the legacy automaker GM by 10.44%, as it shed 60 million shares, lowering its total stake in GM to $3.55 billion at the end of June, compared with $3.85 billion a quarter ago.

Apple, GM, Kroger, AbbVie, Merck, Bristol Myers Squibb, Biogen — How Warren Buffett's Berkshire Adjusted Its Portfolio In Q2

Axalta Coating Systems

Liberty Global Ltd

Marsh & McLennan

U.S. Bancorp

Berkshire Hathaway CEO Warren Buffett and his team were bears yet again in Q2 2021, hacking away at a large number of positions while only adding to a handful.

11 Stocks Warren Buffett Is Selling (And 3 He's Buying)

Warren Buffett's Berkshire Hathaway Inc said on Monday it trimmed or eliminated its stakes in several pharmaceutical companies, and reported a small new stake in a Merck & Co spinoff, Organon & Co.

Buffett's Berkshire pares drug holdings, sheds Axalta, Biogen

Merck's (MRK) Welireg (belzutifan) is the first and only systemic therapy approved for treating patients with certain types of von Hippel-Lindau (VHL) disease-associated tumors.

Merck's (MRK) VHL-Linked Tumor Drug Welireg Gets FDA Nod

The FDA on Friday approved Merck & Co Inc's (NYSE: MRK) belzutifan for patients with the rare disorder known as von Hippel-Lindau (VHL) disease.  VHL is a rare genetic disease that causes tumors and cysts to grow throughout the body.

Merck's Belzutifan Wins FDA Approval As First Drug For Rare VHL Tumors

Pfizer

Pfizer traded up to its May '99 all-time-high this week after lagging for 21 years. Merck traded up to its December '2000, all-time-high of $87.25 in early 2020, but has traded lower since.

Pfizer And Merck: Two Long-Term Laggards In A Momentum Market, As Pfizer Gets A Catalyst From Covid-19

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MERCK--FDA Approves Merck's Hypoxia-Inducible Factor-2 Alpha Inhibitor WELIREG™ for Treatment of Patients With Certain VHL Disease-Associated Tumors

FDA Approves Merck's Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors

FDA approves Merck's (MRK) Keytruda + partenr Eisai's Lenvima for advanced RCC in the first-line setting based on data from the phase III CLEAR/KEYNOTE-581 study.

Merck's (MRK) Keytruda/Lenvima Get FDA Nod for Kidney Cancer

KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug Administration (FDA) has approved the combination of KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). The approval is based on results from

FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma (RCC)

Atea Pharmaceuticals

Moderna

Sorrento Therapeutics Inc

Vaxart

You may have thought the moment of relevancy for these biotech stocks was over, but the Delta variant has changed their prospects. The post 7 Biotech Stocks to Buy Amid the Delta Variant's Onslaught appeared first on InvestorPlace.

News for Merck Stock (MRK)